Bristol Myers Squibb (NYSE: BMY) recently reported its Q4 results, surpassing street estimates with revenue of $11.5 billion and adjusted earnings of $1.70 per share. This exceeded consensus estimates of $11.2 billion in sales and $1.53 profit per share. Despite facing near-term challenges from biosimilar competition for Revlimid, analysts believe BMY stock has significant growth potential.
Over the past three years, BMY stock has experienced fluctuations, declining 15% from early 2021 levels of $60 to around $50 currently. While the stock underperformed the S&P 500 in 2021 and 2023, it outperformed in 2022. Comparatively, the Trefis High Quality Portfolio, consisting of 30 stocks, consistently outperformed the S&P 500 during the same period, showcasing better returns with lower risk.
